Homology Medicines Announces Closing of Initial Public Offering

BEDFORD, Mass., April 3, 2018 – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the closing of its initial public offering of 10,350,000 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,350,000 additional shares. The gross proceeds to Homology, before underwriting discounts and commissions, are $165,600,000. All of the shares of common stock in the offering were sold by Homology. The Company’s common stock began trading on the Nasdaq Global Select Market on March 28, 2018 under the ticker symbol “FIXX.”

BofA Merrill Lynch, Cowen and Evercore ISI acted as joint book-running managers for the offering. BTIG acted as the lead manager for the offering.

A registration statement relating to the securities in the offering was declared effective by the Securities and Exchange Commission. This offering was made by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Theresa McNeely
SVP, Corporate Communications & Patient Advocacy
tmcneely@homologymedicines.com
508-523-9511

< BACK